A prospective study investigating effect of polymorphisms in CYP2D6, ABCB1, and ABCG2 and the side effects induced by gefitinib on pharmacokinetics of of O-desmethyl gefitinib in japanese subjects with advanced non-small cell lung cancer.

Trial Profile

A prospective study investigating effect of polymorphisms in CYP2D6, ABCB1, and ABCG2 and the side effects induced by gefitinib on pharmacokinetics of of O-desmethyl gefitinib in japanese subjects with advanced non-small cell lung cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Mar 2017

At a glance

  • Drugs Gefitinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Pharmacokinetics
  • Most Recent Events

    • 01 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top